1993 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Michelino De Laurentiis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 73 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Biomarkers in triple-negative breast cancer: State-of-the-art and future perspectives

Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Lauro, V. D., Fusco, G., Gioia, G. D., Licenziato, M. & de Laurentiis, M., Jul 2020, In : International Journal of Molecular Sciences. 21, 13, p. 1-33 33 p., 4579.

Research output: Contribution to journalReview article

Open Access
  • Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

    investigators, O. B. O. T. GIM., Lambertini, M., Poggio, F., Bruzzone, M., Conte, B., Bighin, C., de Azambuja, E., Giuliano, M., De Laurentiis, M., Cognetti, F., Fabi, A., Bisagni, G., Durando, A., Turletti, A., Urracci, Y., Garrone, O., Puglisi, F., Montemurro, F., Ceppi, M. & Del Mastro, L., 2020, In : Int. J. Cancer.

    Research output: Contribution to journalArticle

  • Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

    Cortés, J., Diéras, V., Lorenzen, S., Montemurro, F., Riera-Knorrenschild, J., Thuss-Patience, P., Allegrini, G., De Laurentiis, M., Lohrisch, C., Oravcová, E., Perez-Garcia, J. M., Ricci, F., Sakaeva, D., Serpanchy, R., Šufliarský, J., Vidal, M., Irahara, N., Wohlfarth, C., Aout, M. & Gelmon, K., Jun 25 2020, In : JAMA oncology.

    Research output: Contribution to journalArticle

  • Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

    Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 31 others, La Verde, N., Bianchi, G. V., Artale, S., Blasi, L., De Laurentiis, M., Atzori, F., Turletti, A., Porpiglia, M., Santini, D., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Giordano, M., Donadio, M., Biganzoli, L., Del Mastro, L., Bisagni, G., Livi, L., Natoli, C., Montemurro, F., Riccardi, F., Romagnoli, E., Marchetti, P., Torri, V., Pronzato, P. & Mustacchi, G., Jan 1 2020, In : Breast Care. 15, p. 30-37 8 p.

    Research output: Contribution to journalArticle

  • Long non-coding rna hotair in breast cancer therapy

    Cantile, M., Di Bonito, M., Cerrone, M., Collina, F., De Laurentiis, M. & Botti, G., May 2020, In : Cancers. 12, 5, 1197.

    Research output: Contribution to journalReview article

    Open Access